Daniel Fischer is President and CEO of Tevard Biosciences. As a co-founder, he has shaped the company’s mission to develop transformative genetic medicines for rare diseases, inspired by his personal experience as a parent to a daughter with Dravet syndrome. Since Tevard’s launch, Daniel has guided the company’s pioneering tRNA-based gene therapy platforms, progressed programs in cardiovascular disease and neurological disorders to drug candidate selection, and forged key partnerships.
Daniel has over 25 years of executive leadership and entrepreneurial experience, spanning innovative biotechnology ventures, patient advocacy, and global business strategy. Before co-founding Tevard, he led program development at MIT’s Industrial Liaison Program, served as a Director at the Epilepsy Therapy Project (Epilepsy Foundation), and held founder and consulting roles at Intellimedix, Comerxia, A.T. Kearney, and Arthur D. Little, among others.
Daniel holds an MBA from IESA and completed executive education in finance at The Wharton School. He earned a BSEE in Electronics and Telecommunications from Universidad Simón Bolívar, including a semester at Tel Aviv University.